Gong Bo, Liu Yi, Li Huan, Ju Xueming, Li Dongfeng, Zou Yuhao, Guo Xiaoxin, Dong Kai, Xiao Jialing, Wu Weijia, Chai Renjie, Zhang Ruifan, Yu Man
Department of Ophthalmology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610000, China.
Human Disease Genes Key Laboratory of Sichuan Province and Institute of Laboratory Medicine, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610000, China.
Adv Sci (Weinh). 2025 Apr;12(15):e2404835. doi: 10.1002/advs.202404835. Epub 2025 Feb 22.
Dry eye disease (DED) is a multifactorial illness affecting tears and the ocular surface. The neurokinin 1 receptor (NK1R) is a target for controlling T helper 17 (Th17) and regulatory T cell (Treg) imbalances. This work creates a silk fibroin (SF) nanoparticle hydrogel that targets NK1R with CP-99,994 (CP). Combining CP and SF to generate stable nanoparticles while integrating a flexible hydrogel material results in a sustained-release ophthalmic drop formulation (SF@CP@Gel), which provides a long-lasting ocular formulation with anti-inflammatory and reparative properties. SF@CP@Gel could maintain a stable CP concentration for 25 h with detectable biological activity. The cell counting kit-8 and 2,7-DHL-DA results reveal that SF@CP@Gel has no cytotoxic effect on human corneal epithelial cells (HCECs) and decreases the reactive oxygen species level in oxidatively damaged HCECs. Cell scratch assays demonstrate that SF@CP@Gel can greatly increase HCEC migration and proliferation within 24 h. Furthermore, in vivo therapy with topical SF@CP@Gel twice daily markedly reduce clinical symptoms by reducing the amount of pathogenic Th17 cells while efficiently restoring Treg activity. In summary, this work reveals that SF@CP@Gel might attenuate DED by inhibiting NK1R-mediated SP signaling and thereby modulating the Th17/Treg ratio, a potential anti-inflammatory and repair treatment method for DED.
干眼症(DED)是一种影响泪液和眼表的多因素疾病。神经激肽1受体(NK1R)是控制辅助性T细胞17(Th17)和调节性T细胞(Treg)失衡的靶点。这项工作制备了一种丝素蛋白(SF)纳米颗粒水凝胶,其用CP-99,994(CP)靶向NK1R。将CP与SF结合以生成稳定的纳米颗粒,同时整合一种柔性水凝胶材料,得到一种缓释滴眼剂配方(SF@CP@凝胶),它提供了一种具有抗炎和修复特性的长效眼部制剂。SF@CP@凝胶可在25小时内维持稳定的CP浓度,并具有可检测的生物活性。细胞计数试剂盒-8和2,7-二氯二氢荧光素二乙酸酯结果显示,SF@CP@凝胶对人角膜上皮细胞(HCECs)无细胞毒性作用,并降低了氧化损伤的HCECs中的活性氧水平。细胞划痕试验表明,SF@CP@凝胶可在24小时内显著增加HCEC的迁移和增殖。此外,每天两次局部应用SF@CP@凝胶进行体内治疗,可通过减少致病性Th17细胞数量并有效恢复Treg活性,显著减轻临床症状。总之,这项工作表明,SF@CP@凝胶可能通过抑制NK1R介导的P物质信号传导,从而调节Th17/Treg比值来减轻干眼症,这是一种针对干眼症的潜在抗炎和修复治疗方法。